GlassScriptPhysician profile
Blake J Randolph
NPI 1285051144
$1,646.76
in general payments reported to CMS, 2019-2025
24 companies · $288 in 2025
The $288 reported for 2025 was more than what 84% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $637 · 2020: $96.72 · 2021: $18.83 · 2022: $119 · 2023: $171 · 2024: $316 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $774.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $184.73 | 2019-2024 | Gardasil 9, Vaxneuvance, Vaxelis |
| Corium, LLC | $174.09 | 2022-2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $169.85 | 2019-2024 | |
| Cranial Technologies, INC | $145.69 | 2019-2025 | Doc Band |
| Sanofi Pasteur INC. | $122.16 | 2019-2025 | |
| Kaleo, INC. | $99.10 | 2019-2024 | Auvi-Q |
| Neos Therapeutics, LP | $97.04 | 2019-2024 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Collegium Pharmaceutical, INC. | $71.66 | 2025 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $70.76 | 2021-2025 | Qelbree |
| Vertical Pharmaceuticals, LLC | $65.82 | 2019-2025 | Relexxii |
| Tris Pharma INC | $65.40 | 2019-2020 | |
| Glaxosmithkline, LLC. | $61.39 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.86 | 2019-2020 | |
| Hologic Sales and Service, LLC | $45.48 | 2019-2020 | |
| Seqirus USA INC | $32.58 | 2023-2025 | Flucelvax, Flucelvax Quadrivalent |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $31.44 | 2019 | |
| Adlon Therapeutics L.P. | $28.66 | 2019 | |
| Sanofi-Aventis U.S. LLC | $28.22 | 2024 | |
| Alk-Abello, INC | $22.48 | 2025 | Neffy |
| Verrica Pharmaceuticals INC. | $18.23 | 2024 | Ycanth |
| Phadia US INC. | $17.87 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $16.45 | 2025 | Neffy |
| Organon LLC | $15.58 | 2025 | Nexplanon |
| Shire North American Group INC | $13.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blake Randolph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.